Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Condition(s) studied

Investigational drug(s) / intervention(s)

Plasma sample collection: Collect at least two plasma samples

Study summary

The PROPHETIC study is a prospective, multi-center, international clinical study aimed at developing an algorithm to predict patient outcomes. The study involves analyzing the proteomic profiles of patients undergoing therapy to assess the likelihood of clinical benefit from their prescribed treatment. Blood samples are collected prior to and during the treatment period and analyzed as part of the ongoing development of thealgorithm.

Eligibility

Primary outcome measure(s)

• Measured biological features at baseline (pre-treatment) and after 1st dose administration (on-treatment) and during treatment (optional) — Measured biological features are analyzed in samples taken at baseline (prior treatment) and after the 1st dose administration (on-treatment) and during treatment (optional)
  Biological features are analyzed in biological samples taken from the patients as part of the study
• Overall response as determined by RECIST 1.1 or any other validated clinical scales for response, every 3 months or according to the standard of care — Every 3 months or according to the standard of care
  Overall response as determined by RECIST 1.1 or any other validated clinical scales for response, every 3 months or according to the standard of care
• Progression Free Survival (PFS) — At progression during treatment
  Collect Progression Free Survival (PFS) dates
• Overall survival or last follow-up — Overall survival or last follow-up
  Collect overall survival or last follow-up dates

Trial sites (41)

+ 1 more sites — see the full list on the official registry below.